Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (slL-2R) concentrations in peripheral blood as markers of pituitary tumours

Cytobios

Volumn 2000, Issue 398, 2000, Pages 151-159

  Komorowski, Jan ^a   Jankewicz, Joanna ^a   Stȩpień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

bFGF; Pituitary tumours; slL 2R; VEGF

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 2 RECEPTOR; LYMPHOKINE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, INTERLEUKIN-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033629255     PISSN: 00114529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ARZT E., Sauer J., Buric R., Stalls J., Renner U. and Stalla G. K. 1995. Characterization of interleukin-2 (IL-2) receptor expression and action of IL-2 and IL-6 on normal anterior pituitary cell growth. Endocrine 3 113-9.
2. ARZT E., Buric R., Stelzer G., Stalla J., Renner U. and Stalla G. K. 1993. Interleukin involvement in anterior pituitary cell growth regulation: effects of interleukin-2 (IL-2) and IL-6. Endocrinology 132 459-67.
3. ARZT E., Stelzer G., Renner U., Lange M., Müller O. A. and Stalla G. K. 1992. Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures. J. clin. Invest. 90 1944-51.
4. BANERJEE S. K., Sarkar D. K., Weston A. P. and Campbell D. R. 1997. Overexpression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumours may mediate estrogen-initiated tumour angiogenesis. Carcinogenesls 18 1155-61.
5. BASILICO C. and Moscatelli D. 1992. The family of growth factors and oncogenes. Adv. Cancer Res. 59 115-65.
6. BLOOD C. H. and Zetter B. R. 1990. Tumour interactions with the vasculature: angiogenesis and tumour metastasis. Biochim. biophys. Acta 1032 89-118.
7. BUSSOLINO F., Albini A., Camussi G., Presta M., Viglietto G., Ziehe M. and Persico G. 1996. Role of soluble mediators in angiogenesis. Eur. J. Cancer. 32 2401-12.
8. DIRIX L. Y., Vermeulen P. B., Pawiński A., Prove A., Benoy I., De Pooter C., Marti M. and Van Oostertom A. T. 1997. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 76 238-43.
9. ELIAS K. A. and Weiner R. I. 1984. Direct arterial vascularization of estrogen-induced prolactin secreting anterior pituitary tumours. Proc. natn. Acad. Sci. U.S.A. 81 4549-53.
10. ERROI A., Bassetti M., Spada A. and Giannattasio G. 1986. Microvasculature of human micro-and macroprolactinomas: a morphological study. Neuroendocrinology 43 159-65.
11. FARNOU M. R., Lissak B., Kujas M., Peillon F., Racadot J. and Li J. Y. 1992. Specific alteration of the basement membrane and stroma antigens in human pituitary tumours in comparison with the normal anterior pituitary: an immunocytochemical study. Virchows Arch. path. Anat. 421 449-55.
12. FOLKMAN J. 1997. Cancer: principles and practice in oncology. Fifth editn. pp 3075-85. Lippincott Raven Publishers.
13. FOLKMAN J. 1998. (Editorial) Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139 441-2.
14. GORCZYCA W. and Hardy J. 1988. Microadenomas of the human pituitary and heir vascularization. Neurosurgery 22 1-6.
15. JUGENBURG M., Kovacs K., Jugenburg I. and Scheithauer B. W. 1997. Angiogenesis in endocrine neoplasms. Endocr. Path. 4 259-72.
16. JUGENBURG M., Kovacs K., Stefaneanu L. and Scheithauer B. W. 1995. Vasculature in non-tumorous hypophyses, pituitary adenomas, and carcinomas: quantitative morphologic study. Endocr. Path. 6 115-24.
17. KATZNELSON L., Alexander J. M. and Klibanski A. 1993. Clinically nonfunctioning pituitary adenomas. J. clin. Endocr. Metab. 76 1089-94.
18. KOMOROWSKI J., Gradowski G. and Stȩpień H. 1997. Effects of hCG and β-hCG on IL-2 and slL-2R secretion from human peripheral blood mononuclear cells. A dose-response study in vitro. Immun. Letters 59 29-33.
19. KUNERT-RADEK J., Radek A. and Stȩpień H. 1994. Interleukin-2 stimulates cell proliferation of the growth hormone producing human pituitary adenoma in vitro. Biomeical Letters 49 259-64.
20. MANTOVANI A., Bussolino F. and Dejana E. 1992. Cytokine regulation of endothelial cell function. FASEB J. 6 2591-9.
21. MELMED S. 1997. The gp 130-related cytokines and their receptors in the pituitary. TEM 8 391-7.
22. MORISAKI A. K., Katano M., Ikubo A., Kisuki H., Uchiyama A., Kuroki S., Tanaka M. and Torisu M. 1996. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119 333-9.
23. RENNER U., Pagotto U., Arzt B. and Stalla G. K. 1996. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur. J. Endocr. 135 515-32.
24. ROY A. F., Olsen N. J., Spencer-Green G., Kiang-Teck Y., Tet-Kin Y., Berse B., Jackman R. W., Senger D. R., Dvorak H. F. and Brown L. F. 1994. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. exp. Med. 180 341-6.
25. RUBIN L. A. and Nelson D.L. 1990. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Int. Med. 113 619-27.
26. SMITH K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240 1169-76.
27. STEPIEN H., Grochal M., Zieliński K. W., Mucha S., Kunert-Radek J., Kulig A., Stawowy A. and Pisarek H. 1996. Inhibitory effect of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fisher 344 rats. J. Endocr. 150 99-106.
28. THAPAR K., Kovacs K. and Horvath B. 1995. Morphology of the pituitary in health and disease. In Principles and Practice of Endocrinology and Metabolism, pp 103-29. Edited by K. L. Becker.
29. WEIDNER N., Folkman J., Pozza F., Bevilacqua P., Allred B. N., Moore D. H., Meli S. and Gasparini G. 1992. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. natn. Cancer lnst. 84 1875-87.
30. ZORN U., Dallmen I., Grosse J., Kirchner H., Paliwoda H. and Atzpodien J. 1994. Soluble interleukin-2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. Cytokine 6 358-64.